Additional pharmacokinetic data of HGF.
journal contribution
posted on 2024-07-11, 17:51 authored by Venkataramanan Srinivasan, Victoria Homer, Darren Barton, Abigail Clutterbuck-James, Siân Jenkins, Claire Potter, Kristian Brock, Ann Logan, Donna Smith, Lars Bruce, Zsuzsanna Nagy, Simon P. BachPharmacokinetics for HGF detected within the ALS trial.
(DOCX)
History
Usage metrics
Categories
Keywords
sustained weekly administrationsource data verificationresolved without sequalaerare neurological conditionmoderate adverse eventsintolerable events occurringel escorial criteriae6 r2 guidelinescumulative dose rangingamyotrophic lateral sclerosisprimary outcome datamotor cortex leadingsingle uk hospitalphase ii trialleast 18 yearsclinical trials ”acceptable safety profileterm weekly ilbclinical trialsterm followprimary outcomesmotor neurons“ conditionswell toleratedtrial adherestotal numbersuspended earlyspinal cordspecific losssi 2006risk statusrespiratory supportprogressive paralysisperform 100part 2neuroprotective medicationinternational conferencefinal ilbexternal databasebrain stemarticles 2also known6668 mg62 weeks270 mild2 mg1928 ).19 pandemic
Licence
Exports
RefWorks
BibTeX
Ref. manager
Endnote
DataCite
NLM
DC